anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic graft rejection represents a significant threat to long-term graft survival. Early diagnosis, understanding of the immunological mechanisms and appropriate therapeutic management are essential to improve graft survival and quality of life for transplant patients. Knowing which immune cells are responsible for chronic vascular rejection would allow us to provide effective and appropriate treatment for these patients. It is now widely accepted that natural killer (NK) cells play an important role in chronic vascular rejection. They can either initiate chronic vascular rejection by recognizing missing self on the graft or be recruited by donor-specific antibodies to destroy the graft during antibody-mediated rejection. Whatever the mechanisms of activation of NK cells, they need to be primed to become fully activated and damaging to the graft. A better understanding of the signaling pathways involved in NK cell priming and activation would pave the way for the development of new therapeutic strategies to cure chronic vascular rejection. This review examines the critical role of NK cells in the complex context of chronic vascular rejection.
OBJECTIVES: To develop and validate a prediction tool for pediatric acute liver failure (PALF) mortality risks that captures the rapid and heterogeneous clinical course for accurate and updated prediction.
METHODS: Data included 1144 participants with PALF enrolled during three phases of the PALF registry study over 15 years. Using joint modeling, we built a dynamic prediction tool for mortality by combining longitudinal trajectories of multiple laboratory and clinical variables. The predictive performance for 7-day and 21-day mortality was assessed using the area under curve (AUC) through cross-validation and split-by-time validation.
RESULTS: We constructed a prognostic joint model that combines the temporal trajectories of international normalized ratio, total bilirubin, hepatic encephalopathy, platelet count, and serum creatinine. Dynamic prediction using updated information improved predictive performance over static prediction using the information at enrollment (Day 0) only. In cross-validation, AUC increased from 0.784 to 0.887 when measurements obtained between Days 1 and 2 were incorporated. AUC remained similar when we used the earlier subset of the sample for training and the later subset for testing.
CONCLUSIONS: Serial measurements of five variables in the first few days of PALF capture the dynamic clinical course of the disease and improve risk prediction for mortality. Continuous disease monitoring and updating risk prognosis are beneficial for timely and judicious medical decisions.
Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
A method of preserving formulations is provided. The method includes the ste p of including a derivatized cyclodextrin in a formulation capable of sustaini ng microbial growth. One embodiment of the formulation employs a sulfoalkyl eth er cyclodextrin as a preservative and optionally as a solubilizing and complexi ng agent. A suitable cyclodextrin is the CAPTISOL" brand cyclodextrin (sulfobut yl ether R-cyclodextrin). Whether or not the formulation includes a conventiona l preservative, the formulation will remain preserved for at least a minimum predetermined period. Specific embodiments of the invention include a carrie r, a derivatized cyclodextrin and optionally one or more active agents, one or more water activity-reducing agents, and/or one or more complexation-enhanci ng agents. The derivatized cyclodextrin reduces the water activity of the formulation. A liquid formulation can be lyophilized or otherwise dried to yield a solid formulation that is optionally reconstitutable.
INTRODUCTION AND OBJECTIVE: Modern and intelligent triage systems are used today due to the growing trend of disasters and emergencies worldwide and the increase in the number of injured people facing the challenge of using traditional triage methods. The main objective of this study is to investigate the application of artificial intelligence and Technology in the triage of patients injured by disasters and emergencies and the challenges of the implementation of intelligent triage systems.
METHOD: The present study is a systematic review and follows PRISMA guidelines. The protocol of this study was registered in PROSPERO with the code CRD42023471415. To find relevant studies, the databases PubMed, Scopus and Web of Science (ISI) were searched without a time limit until September 2024. The scientific search engine Google Scholar and the references of the final articles were read manually for the final review.
RESULTS: The search identified 2,630 articles, narrowing down to 19 high-quality studies on AI in triage, which improved patient care through optimized resource management and real-time data transmission. AI algorithms like OpenPose and YOLO enhanced efficiency in mass casualty incidents, while e-triage systems allowed for continuous vital sign monitoring and faster triaging. AI tools demonstrated high accuracy in diagnosing COVID-19 (94.57%). Implementing intelligent triage systems faced challenges such as trust issues, training needs, equipment shortages, and data privacy concerns.
CONCLUSION: Developing assessment systems using artificial intelligence enables timely treatment and better resuscitation services for people injured in disasters. For future studies, we recommend designing intelligent triage systems to remove the obstacles in triaging children and disabled people in disasters.
Premature Closure of Fetal Ductus Arteriosus

Avoid use of NSAIDs, including naproxen tablets, in pregnant women at about 30 weeks of gestation and later. NSAIDs, including naproxen tablets increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

Oligohydramnios/Neonatal Renal Impairment

Use of NSAIDs, including naproxen tablets, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit naproxen tablets use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if naproxen treatment extends beyond 48 hours. Discontinue naproxen tablets if oligohydramnios occurs and follow up according to clinical practice [ see Use in Specific Populations (8.1)].
Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition(s) for severe COVID-19 disease presentation \[including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, and one of the following: respiratory rate \> 30 breaths/min; severe respiratory distress; or oxygen saturation (SpO2) \< 90% on room air\] or for critical COVID-19 disease presentation \[including acute respiratory distress syndrome (ARDS), sepsis, septic shock or other complications such as acute pulmonary embolism, acute coronary syndrome, acute stroke and delirium\] at the time of hospitalization.
An intravenous drip monitoring method is provided. (A) A monitoring initializing signal is received. (B) A loaded weight is measured to be assigned to be an initial weight and a current weight when the loaded weight is smaller than an empty weight in (C). (D) An alert weight is calculated such that the predetermined minimum alert weight is assigned to be the alert weight. (E) The loaded weight is measured and assigned to be the current weight. (F) When the current weight is not smaller than the alert weight, (E) is performed. (G) When the current weight is between the alert weight and the empty weight, an alert module generates an alert signal and (E) is performed. (H) When the current weight is smaller than the empty weight, a reset to zero and a zero offset calibration is performed on the weighting module and (C) is performed.
This study aims to evaluate the accuracy of L-shaped reduction malarplasty with bone setback or resection on the zygoma and the mortice and tenon joint structure on the zygomatic arch under the guidance of virtual surgical planning (VSP). Adult patients with zygomatic protrusion or hypertrophy were enrolled and divided. L-shaped reduction malarplasty with or without bone resection and with the mortice and tenon joint structure on the zygomatic arch was conducted either by digital procedures comprising VSP and three-dimensional (3D) printing titanium templates (Group I) or by conventional methods (Group II). Positions of representative landmarks and superimposition models were analyzed by 3D cephalometry. Satisfaction rate and incidences of clinical complications were compared as well. Satisfactory reduction of zygomatic protrusion or hypertrophy was recognized among all 78 patients. Improved symmetry and great surgical accuracy were observed according to the cephalometry analyses. The bone segment movement of virtual plans and actual results in Group I were measured and showed no obvious difference for the inward movement (5.42 ± 0.98 mm vs. 5.33± 0.93 mm, P = 0.6906) and the sagittal overlap (4.77 ± 1.32 mm vs. 4.87± 1.21 mm, P = 0.7386) at the zygoma roots, along with the step length at the long-arm of the L-shaped osteotomy line (2.43 ± 1.11 mm vs. 2.39± 0.89 mm, P = 0.8665). The high resemblance between virtual plans and actual results was depicted via superimposition models. Meanwhile, a higher satisfaction rate (28 in 36, 78% vs. 20 in 42, 48%) and a lower incidence rate of complications (11 in 36, 31% vs. 21 in 42, 50%) were found in Group I. Within the limitations of the study it seems that the application of VSP in reduction malarplasty could significantly contribute to better surgical accuracy and reduced difficulties in the operation, which would be beneficial to patients with zygoma hypertrophy or prominence.
OBJECTIVES: Elevation of the systemic immune inflammation (SII) index and system inflammation response index (SIRI) is known to be associated with higher risk of stroke and all-cause death. However, no study has reported their correlation with early neurological deterioration (END) following recombinant tissue-type plasminogen activator (IV-rtPA) in acute ischemic stroke patients. The aim of this study was to explore the correlation of SII and SIRI with the risk of END after IV-rtPA.
METHODS: Included in this study were 466 consecutive patients treated with IV-rtPA. SII and SIRI were calculated according to blood cell counts before IV-rtPA. Patients were divided into 3 groups based on trisectional quantiles according to SII and SIRI values. The risk of END was assessed by multivariate regression. The overall discriminative ability of SII and SIRI in predicting END was assessed by receiver operating characteristic curve analysis.
RESULTS: Of the 466 included patients, 62 (13.3%) were identified as having END. Compared with the first tertile of SII, multivariable regression analysis demonstrated that patients were more likely to have END (odds ratio 2.54; 95% CI: 1.23-5.23) and poor outcome at 90 days (odds ratio 2.02; 95% CI: 1.06-3.86) in third tertile after adjustment for potential confounders. In addition, a cutoff value of 591.63 for SII was detected in predicting post-thrombolysis END with a sensitivity of 58.1% and a specificity of 64.6% (area under the curve 0.61; 95% CI: 0.54-0.69).
CONCLUSIONS: Higher SII but not SIRI may prove to be a predictor for high risk of END and a poor functional outcome at 90 days after IV-rtPA.
The purpose of this protocol is to study the reproducibility of strain rate (SR) echocardiography in normal volunteers and patients with cardiovascular disease. Tissue Doppler ultrasound is a technology which has been validated for the analysis of global and regional left ventricular function and strain and SR measurements are derived from tissue Doppler imaging (TDI) data. Over the last few years, several improvements in echo machine hardware and software have facilitated the rapid acquisition and analysis of tissue Doppler data, and therefore, strain and strain rate information has become easily accessible. Recent publications have demonstrated the usefulness of these techniques in the analysis of systolic and diastolic function of the left ventricle, and in the detection of regional wall motion and ischemia. Several protocols recently initiated in the Cardiovascular Branch involve echocardiographic imaging and include applications of TDI as their primary or secondary endpoints. Therefore, the purpose of this protocol is to allow development of standardized acquisition and analysis methods of TDI for our cardiology protocols and to evaluate the reproducibility of TDI, SR, and strain measurements.
This control group will be untreated for 8 weeks as to be a controlled group. Then all participants in the control group will be randomised again to either Mg-B1 or B1-Mg groups for another 8 weeks (delayed-start intervention).
Inborn errors of immunity (IEI) are a wide number of conditions featured by impaired immune response, and their classification is in a continuous update, with the discovery of new clinical entities (1). Historically, the warning signs to identify children at risk of IEI have been defined according to the susceptibility to multiple or severe infectious diseases. High recurrence of infections, severe infections with need for hospitalization, use of intravenous antibiotics, and delayed resolution (and recently, infections by unusual pathogens or restricted pathogen susceptibility) are universally recognized as "red flags" for IEI . Recent advances in the clinical comprehension of IEI, together with the expansion of their genetic background and the formulation of specific genotype-phenotype correlations, allowed the better characterization of the non-infectious manifestations of IEI Specifically, the immune dysregulation observed in patients with IEI is clinically expressed with autoimmunity, atopy, and lymphoproliferation, and these manifestations represent the first sign of the disease in about 10% of the patients. Additionally, new diseases with predominant immune dysregulation phenotype in absence of a significant increase of infections have been identified, leading to an extension of the paradigm of immunodeficiency During the diagnostic work-up, patients with non-infectious onset of IEI are frequently addressed to different specialists, including hematologists, endocrinologists, rheumatologists, and allergologists, often resulting in a delayed diagnosis. In this paper, we provide a brief review on the non-infectious manifestations of IEI potentially evidenced at disease onset, focusing on the specific items to be considered for the different clinical specialists
Determination of Ultraviolet A Protection Factor (PFA). Following FDA guidelines, test sites exposed to UVA are scored for pigmentation responses 2 to 4 hours post-exposure.
BACKGROUND: In the last decade, therapy using multipotent mesenchymal stromal cells (MSCs) has offered hope for regenerating the lungs of preterm babies with chronic lung disease. Due to similar disease mechanisms, it is logical to explore the potential impact of MSC therapy on pulmonary hypoplasia in congenital diaphragmatic hernia. Furthermore, MSCs may also contribute to the regeneration of the intestines affected by adhesive small bowel obstruction in patients with congenital diaphragmatic hernia.
CASE PRESENTATION: A female newborn, delivered at 32 weeks and six days gestational age, was diagnosed with a left congenital diaphragmatic hernia. After surgical repair and respiratory/nutritional support for 39 days, she was still dependent on a ventilator and total parenteral nutrition. Two MSC treatments were given a week apart: 10 million cells/kg intratracheally and 5 million cells/kg intravenously. She was extubated, and her enteral nutrition improved after the treatment. No side effects were detected. We present the first documented case using MSCs derived from the umbilical cord to simultaneously treat pulmonary hypoplasia and adhesive small bowel obstruction of congenital diaphragmatic hernia.
CONCLUSION: Although MSC treatment is very promising for pulmonary hypoplasia and adhesive small bowel disease of congenital diaphragmatic hernia, much more needs to be learned about potential side effects, appropriate dosage, and the optimal method of administration.
AIM: We investigated the influence of physiological-based cord clamping (PBCC) on cardiorespiratory stability in very low birth weight (VLBW) infants during the first 72 h of life.
METHODS: This retrospective study comprised VLBW infants born at <32 + 0 weeks of gestation and admitted to the neonatal intensive care unit of the Medical University of Graz, Austria, from December 2014 to April 2021. VLBW infants delivered with PBCC were matched by gestational age and birth weight to delayed cord clamping controls. The PBCC group was stabilised after birth with an intact cord. Routine monitoring parameters were compared between the groups.
RESULTS: We included 54 VLBW infants. The mean gestational ages of the PBCC group and controls were 27.4 ± 1.9 versus 27.4 ± 1.8 weeks (p = 0.87), and the mean birth weights were 912 ± 288 versus 915 ± 285 g (p = 0.96), respectively. The mean cord clamping time was 191 ± 78 s in the PBCC group. Heart rate was lower in the PBCC group during the first 3 days after birth, reaching significance by 10 h. Other monitoring parameters did not reveal any differences between the two groups.
CONCLUSION: PBCC stabilised cardiorespiratory parameters in VLBW infants. The lower heart rate in the PBCC group suggested higher blood volume following intact cord resuscitation.
In a first aspect, the present invention relates to a method for prevention or treating memory impairment and/or a neurodegenerative condition, disorder or disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound targeting a miRNA or any precursor, or targeting the activity of said mi RNA or any precursor thereof. In particular, the present invention relates to a method wherein the targeted miRNA is miR-34. Moreover, the present invention relates to a method for improving memory functionality in a subject suffering from memory loss, said method comprises the reduction or reducing the level of miR-34 levels or precursor molecule levels in brain tissue of said subject administering to the subject a therapeutically effective amount of a compound targeting miR-34 or any precursor thereof. Moreover, the present invention relates to a method of inducing memory loss in an individual comprising administering to said individual an effective amount of one or more compounds having the functionality of miR-34, in particular of miR- 34c or any precursor thereof. In addition, a method for diagnosing or predicting memory impairment and/or neurodegenerative condition, disorder or disease is provided. Finally, the present invention relates to a pharmaceutical composition containing a compound targeting miR-34 or precursor molecules thereof.
PURPOSE: This study introduces an algorithm specifically designed for processing unprocessed 12-lead electrocardiogram (ECG) data, with the primary aim of detecting cardiac abnormalities.
METHODS: The proposed model integrates Diagonal State Space Sequence (S4D) model into its architecture, leveraging its effectiveness in capturing dynamics within time-series data. The S4D model is designed with stacked S4D layers for processing raw input data and a simplified decoder using a dense layer for predicting abnormality types. Experimental optimization determines the optimal number of S4D layers, striking a balance between computational efficiency and predictive performance. This comprehensive approach ensures the model's suitability for real-time processing on hardware devices with limited capabilities, offering a streamlined yet effective solution for heart monitoring.
RESULTS: Among the notable features of this algorithm is its strong resilience to noise, enabling the algorithm to achieve an average F1-score of 81.2% and an AUROC of 95.5% in generalization. The model underwent testing specifically on the lead II ECG signal, exhibiting consistent performance with an F1-score of 79.5% and an AUROC of 95.7%.
CONCLUSION: It is characterized by the elimination of pre-processing features and the availability of a low-complexity architecture that makes it suitable for implementation on numerous computing devices because it is easily implementable. Consequently, this algorithm exhibits considerable potential for practical applications in analyzing real-world ECG data. This model can be placed on the cloud for diagnosis. The model was also tested on lead II of the ECG alone and has demonstrated promising results, supporting its potential for on-device application.
Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 orally PO BID on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
A method of enhancing the in vitro and in vivo lifespan of T cells is provided. A method of enhancing the lifespan of T cells is provided. The method includes engineering a T cell to express an exogenous ribonucleic acid (RNA), wherein the RNA includes a nucleic acid encoding telomerase reverse transcriptase (TERT). T cells genetically engineered to transiently express exogenous RNA including the coding sequence of TERT (TERT T cells) are provided. TERT T cells have one or more of the following characteristics when compared to T cells that do not express TERT by exogenously introduced nucleotides: enhanced proliferation in vitro and in vivo, reduced number of senescent cells, and enhanced anticancer activity in vivo. The modified TERT T cells can be used for adoptive cell transfer to treat a subject in need thereof.
BACKGROUND: Chronic airway disease (CAD) is characterized by chronic airway inflammation and colonization of the lungs by pro-inflammatory pathogens. However, while various other bacterial species are present in the lower airways, it is not fully understood how they influence inflammation. We aimed to identify novel anti-inflammatory species present in lower airway samples of patients with CAD.
METHODS: Paired sputum microbiome and inflammatory marker data of adults with CAD across three separate cohorts (Australian asthma and bronchiectasis, Scottish bronchiectasis) was analyzed using Linear discriminant analysis Effect Size (LEfSE) and Spearman correlation analysis to identify species associated with a low inflammatory profile in patients.
RESULTS: We identified the genus Aggregatibacter as more abundant in patients with lower levels of airway inflammatory markers in two CAD cohorts (Australian asthma and bronchiectasis). In addition, the relative abundance of Aggregatibacter was inversely correlated with sputum IL-8 (Australian bronchiectasis) and IL-1β levels (Australian asthma and bronchiectasis). Subsequent in vitro testing, using a physiologically relevant three-dimensional lung epithelial cell model, revealed that Aggregatibacter spp. (i.e. A. actinomycetemcomitans, A. aphrophilus) and their cell-free supernatant exerted anti-inflammatory activity without influencing host cell viability.
CONCLUSIONS: These findings suggest that Aggregatibacter spp. might act to reduce airway inflammation in CAD patients.